GLP-1 and Muscle Loss: How to Keep Your Gains While Losing Fat

Here’s a number that should get your attention: research published in Metabolism found that over 25% of total weight lost during GLP-1 therapy — and bariatric surgery — comes from fat-free mass, including the skeletal muscle you’ve worked hard to build. For men on semaglutide or tirzepatide, that’s not just a cosmetic concern. Losing muscle mass slows your metabolism, compromises physical function, and sets the stage for what researchers call sarcopenic obesity — a condition where body fat creeps back even as you remain weight-stable. The good news is that muscle loss during GLP-1 treatment is not inevitable. It’s a problem with real, evidence-backed solutions.

Why GLP-1 Medications Put Muscle at Risk

GLP-1 receptor agonists work primarily by suppressing appetite and slowing gastric emptying, which creates the calorie deficit responsible for weight loss. As reviewed in the New England Journal of Medicine, these medications produce impressive reductions in body weight and cardiovascular risk — but the same calorie deficit that drives fat loss also signals the body to break down lean tissue. This isn’t unique to GLP-1 drugs. Any significant calorie restriction, whether from dieting, bariatric surgery, or medication, carries this risk. What makes GLP-1 therapy distinctive is the speed and magnitude of the weight loss, which can outpace the body’s ability to preserve muscle without deliberate intervention.

The underlying biology involves the myostatin-activin signaling axis. Stefanakis and colleagues explain that during negative energy balance, activins and myostatin — proteins that actively suppress muscle growth — become more influential, while follistatin, which normally keeps them in check, loses ground. The result is accelerated muscle protein breakdown. A 2025 narrative review in Diabetes Research and Clinical Practice confirmed that both GLP-1 receptor agonists and dual GLP-1/GIP agonists like tirzepatide have been linked to meaningful reductions in lean mass, with some patients meeting clinical criteria for sarcopenia. Older men and those with lower muscle mass at baseline face the steepest risk.

The Non-Negotiable Role of Protein and Resistance Training

If you’re on a GLP-1 medication, or losing weight through any other method, the single most important intervention for preserving muscle is consistent resistance training paired with adequate protein intake. This isn’t a suggestion — it’s a clinical priority. A 2025 joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society explicitly identified resistance training and protein-optimized diet as essential pillars of care for GLP-1 patients, noting that these strategies are underused in real-world practice despite strong evidence.

The protein target that matters here isn’t the outdated 0.8 grams per kilogram of body weight printed on government guidelines. For men in a calorie deficit — medically induced or otherwise — research consistently supports a target closer to 1.6 to 2.2 grams per kilogram of body weight daily, distributed across meals. GLP-1 medications can blunt appetite so effectively that men report eating less than 1,000 calories a day without feeling hungry. That’s a recipe for protein deficiency and rapid muscle loss. The fix is intentional: prioritize high-quality protein sources at every eating opportunity, even when appetite is suppressed. Greek yogurt, eggs, cottage cheese, lean meats, and protein shakes become strategic tools, not optional extras.

On the training side, lifting weights two to four times per week — with a focus on compound movements like squats, deadlifts, rows, and presses — provides the mechanical stimulus muscle needs to resist breakdown signals. Cardio has its place for cardiovascular health, but it cannot substitute for the anabolic signaling that resistance training generates. The advisory from Mozaffarian and colleagues goes further, recommending baseline assessment of muscle strength and body composition before starting GLP-1 therapy, so that losses can be tracked and addressed proactively.

Emerging pharmacological options are also showing promise. A 2024 study in Molecular Metabolism demonstrated that bimagrumab — a monoclonal antibody that blocks activin type II receptors — preserved lean mass and enhanced fat loss in obese mice treated with semaglutide. Animals receiving the combination lost more fat and maintained more muscle than those on semaglutide alone. Compounds like bimagrumab, trevogrumab, and garetosmab are moving through the clinical pipeline as potential adjuncts to GLP-1 therapy specifically to address lean mass preservation — though these remain investigational and aren’t yet standard of care.

What This Means For You

Whether you’re on a GLP-1 medication, running a traditional calorie deficit, or somewhere in between, the threat of muscle loss during weight loss is real — and entirely manageable. Hit your protein targets every day, even on low-appetite days. Train with weights consistently. Get a baseline sense of your body composition so you can measure what’s actually happening, not just what the scale says. And if you’re working with a clinician on GLP-1 therapy, advocate for nutritional support and a structured exercise plan as part of your treatment — not an afterthought. The medications can do a lot of the heavy lifting on fat loss. Keeping your muscle is still your job.